Quick answer
CAR-T cell therapy in China costs roughly $89,000–$170,000 for an approved CD19 or BCMA product including the full treatment course, or about $30,000–$80,000 for clinical-trial participation. China's NMPA has approved seven CAR-T therapies — more than the United States or Europe — including satri-cel, the world's first CAR-T approved for a solid tumor. Leading centres include the Cancer Hospital of CAMS and Peking University People's Hospital in Beijing, Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center in Guangzhou, and West China Lecheng Hospital in the Hainan Lecheng zone. Treatment runs over four to six weeks in China: records review and target-antigen testing, apheresis, a two-to-four-week manufacturing window, lymphodepleting chemotherapy, infusion, and ten to fourteen days of inpatient monitoring.
Who this is for
Typically a good fit if
- Your cancer has come back or stopped responding after at least two lines of treatment
- You have a B-cell lymphoma or B-cell acute lymphoblastic leukaemia — the approved CD19 products cover these
- You have multiple myeloma that has relapsed after several lines of therapy, including a proteasome inhibitor and an IMiD — the approved BCMA products cover this
- You have Claudin18.2-positive gastric or gastro-oesophageal junction adenocarcinoma after at least two prior lines — the indication satri-cel is approved for
- You are well enough for intensive treatment (ECOG 0–1), with adequate heart, liver and kidney function, no active infection, and a tissue sample available for target-antigen testing
May not be suitable if
- A solid tumour other than Claudin18.2-positive gastric or GEJ cancer — approved products cover blood cancers, and other solid-tumour CAR-T remains experimental
- An active bacterial, viral or fungal infection — this has to be stabilised before CAR-T can be considered
- Cancer involving the central nervous system (brain or spinal cord) — generally contraindicated because of the risk
- Poor performance status (ECOG 3 or above) or significant cardiac, hepatic, renal or pulmonary impairment
- Pregnancy, or current HIV infection
Diagnosis
Eligibility depends on the cancer type, how many prior lines of treatment have failed, organ function and the target antigen on the tumor. CD19, BCMA and Claudin18.2 status are confirmed by pathology review before anything else.
Treatment Options
CAR-T involves leukapheresis, a two-to-four-week manufacturing window, lymphodepleting chemotherapy and infusion, followed by roughly ten to fourteen days of inpatient monitoring. China offers both approved products and clinical-trial access to experimental targets.
What the Treatment Involves
- Records review and eligibility3–7 daysSend your diagnosis, pathology report, imaging and treatment history. Target-antigen testing (CD19, BCMA or Claudin18.2) has to be confirmed before anything else, and you receive a preliminary cost quote.
- Visa and travel7–14 daysThe hospital issues an official invitation letter for the M visa, which is normally processed within 4–10 business days.
- Apheresis (T-cell collection)Around weeks 3–4Your T cells are collected by leukapheresis, usually over one or two sessions, and shipped to the manufacturing site.
- Manufacturing window2–4 weeksThe cells are engineered and expanded under GMP conditions. Bridging chemotherapy may be needed so the disease stays controlled while you wait.
- Lymphodepletion and infusion5 days, then 1 dayA short course of fludarabine and cyclophosphamide prepares your body, then the engineered cells are infused and monitoring begins immediately.
- Inpatient monitoring10–14 daysClose observation for cytokine release syndrome and neurological toxicity, with daily cytokine panels and tocilizumab or corticosteroids if needed. Major centres have 24/7 ICU-level backup.
- Discharge and follow-upMonths 1, 3, 6 and 12A PET-CT assesses response before discharge. Later scans and blood tests can be done in your home country with the results shared with the treating team.
Typical Costs in China
Prices are reference ranges; final quotes come from the hospital after case review.
Top Hospitals for CAR-T Cell Therapy
Frequently Asked Questions
Which hospital offers CAR-T therapy in China?
Leading centres include the Cancer Hospital of CAMS and Peking University People's Hospital (Beijing), Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center (Guangzhou), and West China Lecheng Hospital in the Hainan Lecheng zone. Foshan Fosun Chancheng Hospital lists CAR-T among its oncology services. A case review confirms which of these can take your case.
How much does CAR-T therapy cost in China?
Reference ranges: approved CD19 or BCMA CAR-T runs roughly $89,000–$170,000 for the drug plus the full course, and clinical trial participation typically $30,000–$80,000. Budget about $3,500–$10,500 for travel, accommodation and monitoring over the 4–6 week stay. Confirm whether a quote includes tocilizumab, ICU standby and the full monitoring period, which are sometimes billed separately.
Is CAR-T a cure?
No. CAR-T has produced durable remissions in some blood cancers, but it is not a cure and it is not suitable for everyone. Response figures are reported at group level, and the treatment carries real risks including cytokine release syndrome and neurological toxicity.
Am I eligible for CAR-T therapy in China?
Eligibility depends on your cancer type, how many prior treatments have failed, organ function, and the target antigen on your tumour. In general, patients must have progressed after standard therapy, have adequate heart, liver and kidney function, no active infection, and no cancer spread to the central nervous system. A case review with your records and a tissue sample confirms whether you qualify.
What is the difference between approved CAR-T and a clinical trial?
Approved CAR-T products have cleared NMPA review for a defined indication, so the hospital can offer them as standard care. A clinical trial gives access to a product that is not yet approved — it may be more effective for your case, but outcomes are more uncertain and the screening criteria are stricter. Both routes exist in China and they are not interchangeable.
How long do I need to stay in China for CAR-T?
Plan for roughly four to six weeks in China. The sequence covers case review and target testing, apheresis, a manufacturing window of about two to four weeks, lymphodepleting chemotherapy, the infusion itself, and inpatient monitoring for about ten to fourteen days. Later follow-up scans can be done at home.
How this directory is checked
57 Grade 3A hospitals across 13 cities. 20 score 0.9 or above on our verification scale, and 5 were cross-checked against three or more independent sources. Every listing was last verified between 2026-04-06 and 2026-10-13.
Considering treatment for CAR-T Cell Therapy?
Tell us your diagnosis, scans and timing. We'll match you with the right Grade 3A hospital, compare likely costs, and outline the next practical step — free, no commitment.
Start Free Case Review →